🇺🇸 BMY — Bristol-Myers Squibb Company

Salud Compra
← Volver

Precio actual

61,71 USD

Máx. histórico

81,13

1432 días

Split 1000000:951777 del 07/08/2001

Caída desde máximo

-23,94%

Rango 52 semanas

45,27 – 68,64

Variación hoy

-2,08%

Cierre anterior

63,02

Rango de hoy

61,54 – 63,26

Volumen hoy

10.291.599

Peor caída histórica

-70,62%

28/10/1999 → 24/07/2002

Recuperado en 3948 días

Volatilidad anualizada ⓘ

26,37%

Información
Nombre completo
Bristol-Myers Squibb Company
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
32.500
PER ⓘ
13,68 (puede no estar actualizado)
Dividend yield
4,00% (puede no estar actualizado)
Precio objetivo analistas
65,25 USD (puede no estar actualizado)
Primera cotización
01/06/1972
Precio actualizado
hace 14 horas
Sobre la empresa

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Dividendos repartidos Total últimos 12 meses: 2,5200 USD · Yield: 4,08%
Fecha de pago Importe por participación
02/10/2026 0,6300 USD
02/07/2026 0,6300 USD
02/04/2026 0,6300 USD
02/01/2026 0,6300 USD
03/10/2025 0,6200 USD
03/07/2025 0,6200 USD
04/04/2025 0,6200 USD
03/01/2025 0,6200 USD
04/10/2024 0,6000 USD
05/07/2024 0,6000 USD
04/04/2024 0,6000 USD
04/01/2024 0,6000 USD
05/10/2023 0,5700 USD
06/07/2023 0,5700 USD
06/04/2023 0,5700 USD
Splits Registrados en el histórico de precios
Fecha Ratio
07/08/2001 1000000:951777
01/03/1999 2:1
03/03/1997 2:1
10/06/1987 2:1
27/05/1983 2:1
31/05/1977 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
19/12/2023 51,61 52,18 51,46 52,11 +1,50% 1,40% 14.293.000
18/12/2023 51,15 51,49 50,93 51,34 +0,88% 1,09% 14.361.100
15/12/2023 51,16 51,45 50,69 50,89 -1,13% 1,49% 44.147.600
14/12/2023 52,46 52,54 51,00 51,47 -0,75% 2,94% 20.212.600
13/12/2023 50,07 51,86 49,94 51,86 +2,67% 3,83% 15.557.000
12/12/2023 50,80 50,94 49,80 50,51 -1,14% 2,24% 14.215.500
11/12/2023 50,52 51,14 50,27 51,09 +1,55% 1,72% 18.432.900
08/12/2023 50,26 50,54 50,09 50,31 +0,30% 0,90% 10.123.100
07/12/2023 50,30 51,00 49,99 50,16 +0,56% 2,01% 14.710.600
06/12/2023 50,32 50,43 49,78 49,88 -0,70% 1,29% 13.839.800
05/12/2023 49,80 50,40 49,56 50,23 +0,50% 1,69% 12.659.500
04/12/2023 49,96 50,76 49,77 49,98 -0,24% 1,98% 14.238.600
01/12/2023 49,40 50,18 48,93 50,10 +1,46% 2,53% 12.806.400
30/11/2023 48,78 49,40 48,25 49,38 +1,35% 2,36% 17.044.300
29/11/2023 49,06 49,35 48,67 48,72 -0,41% 1,39% 12.653.100
28/11/2023 49,05 49,32 48,82 48,92 -0,20% 1,02% 11.372.800
27/11/2023 49,61 49,72 48,82 49,02 -1,49% 1,81% 17.681.600
24/11/2023 49,75 49,91 49,47 49,76 +0,69% 0,88% 5.085.700
22/11/2023 48,75 49,50 48,56 49,42 +1,94% 1,93% 14.734.800
21/11/2023 48,83 49,04 48,45 48,48 -0,86% 1,21% 14.669.600
20/11/2023 48,78 50,17 48,42 48,90 -3,82% 3,59% 27.943.500
17/11/2023 51,19 51,22 50,60 50,84 +0,00% 1,21% 10.229.500
16/11/2023 51,46 51,74 50,25 50,84 -1,42% 2,90% 14.458.500
15/11/2023 50,27 51,63 50,15 51,57 +2,08% 2,94% 13.407.600
14/11/2023 50,45 51,18 50,26 50,52 +0,74% 1,82% 12.025.300
13/11/2023 50,45 50,67 50,06 50,15 -0,91% 1,21% 12.047.100
10/11/2023 50,61 50,70 49,58 50,61 +0,40% 2,21% 12.697.600
09/11/2023 52,55 52,57 50,37 50,41 -3,83% 4,19% 12.175.400
08/11/2023 52,52 52,58 51,84 52,42 +0,25% 1,41% 11.252.800
07/11/2023 52,81 53,05 52,13 52,29 -0,95% 1,74% 20.836.100